Navigation Links
Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
Date:5/7/2009

PITTSBURGH, May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil Tablets, 500 mg, and Mycophenolate Mofetil Capsules, 250 mg.

Mycophenolate Mofetil is the generic name for Roche's CellCept(R), which is indicated for the prevention of organ rejection in patients receiving kidney, heart or liver transplants. CellCept Tablets, 500 mg, and CellCept Capsules, 250 mg, had annual U.S. sales of approximately $680 million and $367 million, respectively, for the 12 months ending March 31, 2009, according to IMS Health. Mylan has commenced shipping both products.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
4. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
5. Mylan Announces Clarinex(R) Settlement Agreement
6. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
7. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
8. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
9. Mylan Announces Transition of Chief Financial Officer
10. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
11. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... provide first-quality education and high-level training standards to an international multidisciplinary group of ... disorder problems. As a way to further its mission at the grassroots level, ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... CA (PRWEB) , ... January 13, 2017 , ... ... on Body and Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk ... Café and Lounge notes that the many health and wellness benefits linked to ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , January 16, 2017 According to a new ... Opportunity Analysis and Industry Forecast, 2014 - 2022," the global antioxidants market generated ... registering a CAGR of 6.42% during the forecast period. In the natural antioxidants ... volume in 2015. Continue Reading ... ...
(Date:1/16/2017)... , Jan. 16, 2017  Today, Analytics 4 Life ... devices, announced its expansion into JLABS @ ... life science incubators. As a resident in the space, ... medical device development and commercialization expertise. JLABS ... science innovation center that provides a flexible environment for ...
(Date:1/15/2017)... Le conseil d,administration de SurgaColl Technologies Ltd., le développeur ... de tissus humains, annonce la nomination de William (Bill) ... ... est un dirigeant expérimenté à l,international dans l,industrie des dispositifs ... de direction au sein de sociétés internationales spécialisées dans les ...
Breaking Medicine Technology: